WallStreetZenWallStreetZen

NASDAQ: BIOL
Biolase Inc Stock

$0.14+0.00 (+0%)
Updated Feb 29, 2024
BIOL Price
$0.14
Fair Value Price
N/A
Market Cap
$316.96k
52 Week Low
$0.13
52 Week High
$50.00
P/E
0x
P/B
0.95x
P/S
0.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$49.73M
Earnings
-$25.17M
Gross Margin
33.8%
Operating Margin
-43.87%
Profit Margin
-50.6%
Debt to Equity
98.98
Operating Cash Flow
-$17M
Beta
1.15
Next Earnings
Mar 26, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BIOL Overview

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIOL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIOL is good value based on its book value relative to its share price (0.95x), compared to the US Medical Devices industry average (3.98x)
P/B vs Industry Valuation
BIOL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIOL due diligence checks available for Premium users.

Be the first to know about important BIOL news, forecast changes, insider trades & much more!

BIOL News

Valuation

BIOL fair value

Fair Value of BIOL stock based on Discounted Cash Flow (DCF)
Price
$0.14
Fair Value
$20.79
Undervalued by
99.33%
BIOL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIOL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
28.9x
Market
35.21x

BIOL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.95x
Industry
3.98x
BIOL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIOL's financial health

Profit margin

Revenue
$10.9M
Net Income
-$4.6M
Profit Margin
-42%
BIOL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIOL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$38.7M
Liabilities
$32.9M
Debt to equity
98.98
BIOL's short-term assets ($27.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOL's short-term assets ($27.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIOL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.6M
Investing
-$182.0k
Financing
$3.8M
BIOL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BIOL vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
BIOL$316.96k-0.72%-0.00x0.95x
MOTS$393.39k-0.73%-0.02x-0.16x
SINT$587.85k+0.73%-0.02x0.05x
BJDX$977.68k+6.62%-0.08x0.19x
BBLG$1.31M+6.06%-0.07x0.45x

Biolase Stock FAQ

What is Biolase's quote symbol?

(NASDAQ: BIOL) Biolase trades on the NASDAQ under the ticker symbol BIOL. Biolase stock quotes can also be displayed as NASDAQ: BIOL.

If you're new to stock investing, here's how to buy Biolase stock.

What is the 52 week high and low for Biolase (NASDAQ: BIOL)?

(NASDAQ: BIOL) Biolase's 52-week high was $50.00, and its 52-week low was $0.13. It is currently -99.72% from its 52-week high and 4.55% from its 52-week low.

How much is Biolase stock worth today?

(NASDAQ: BIOL) Biolase currently has 2,296,777 outstanding shares. With Biolase stock trading at $0.14 per share, the total value of Biolase stock (market capitalization) is $316.96k.

Biolase stock was originally listed at a price of $38,049.71 in Dec 31, 1997. If you had invested in Biolase stock at $38,049.71, your return over the last 26 years would have been -100%, for an annualized return of -38.23% (not including any dividends or dividend reinvestments).

How much is Biolase's stock price per share?

(NASDAQ: BIOL) Biolase stock price per share is $0.14 today (as of Feb 29, 2024).

What is Biolase's Market Cap?

(NASDAQ: BIOL) Biolase's market cap is $316.96k, as of Mar 1, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biolase's market cap is calculated by multiplying BIOL's current stock price of $0.14 by BIOL's total outstanding shares of 2,296,777.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.